ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INDP Indaptus Therapeutics Inc

2.085
-0.095 (-4.36%)
Last Updated: 15:23:12
Delayed by 15 minutes

Period:

Draw Mode:

Volume 6,888
Bid Price 2.09
Ask Price 2.18
News -
Day High 2.22

Low
1.56

52 Week Range

High
4.08

Day Low 2.0486
Company Name Stock Ticker Symbol Market Type
Indaptus Therapeutics Inc INDP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.095 -4.36% 2.085 15:23:12
Open Price Low Price High Price Close Price Prev Close
2.22 2.0486 2.22 2.18
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
87 6,888 $ 2.14 $ 14,734 - 1.56 - 4.08
Last Trade Time Type Quantity Stock Price Currency
15:31:50 4 $ 2.12 USD

Indaptus Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
82.23M 8.54M - 0 -15.42M -1.81 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Indaptus Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No INDP Message Board. Create One! See More Posts on INDP Message Board See More Message Board Posts

Historical INDP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.492.682.04862.3220,199-0.405-16.27%
1 Month2.262.952.04862.5425,788-0.175-7.74%
3 Months1.632.951.562.3293,8770.45527.91%
6 Months2.233.251.562.3050,739-0.145-6.50%
1 Year2.704.081.562.3333,381-0.615-22.78%
3 Years10.1028.82991.259.31465,552-8.02-79.36%
5 Years10.1028.82991.259.31465,552-8.02-79.36%

Indaptus Therapeutics Description

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Your Recent History

Delayed Upgrade Clock